These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 15321697

  • 1. Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial.
    Patten M, Maas R, Bauer P, Lüderitz B, Sonntag F, Dluzniewski M, Hatala R, Opolski G, Müller HW, Meinertz T, SOPAT Investigators.
    Eur Heart J; 2004 Aug; 25(16):1395-404. PubMed ID: 15321697
    [Abstract] [Full Text] [Related]

  • 2. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial.
    Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G, Prevention of Atrial Fibrillation after Cardioversion Investigators.
    Eur Heart J; 2004 Aug; 25(16):1385-94. PubMed ID: 15302102
    [Abstract] [Full Text] [Related]

  • 3. Event-recorder monitoring in the diagnosis of atrial fibrillation in symptomatic patients: subanalysis of the SOPAT trial.
    Patten M, Maas R, Karim A, Müller HW, Simonovsky R, Meinertz T.
    J Cardiovasc Electrophysiol; 2006 Nov; 17(11):1216-20. PubMed ID: 16987384
    [Abstract] [Full Text] [Related]

  • 4. [Conversion rate and prevention of recurrence of paroxysmal and sustained atrial fibrillation or atrial flutter with verapamil/quinidine].
    Trappe HJ, Pfitzner P.
    Med Klin (Munich); 1996 Oct 15; 91(10):617-25. PubMed ID: 9019638
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine.
    Hohnloser SH, van de Loo A, Baedeker F.
    J Am Coll Cardiol; 1995 Oct 15; 26(4):852-8. PubMed ID: 7560608
    [Abstract] [Full Text] [Related]

  • 6. [Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation--conversion and 12-month follow-up--a randomized comparison].
    Kalusche D, Stockinger J, Betz P, Roskamm H.
    Z Kardiol; 1994 Oct 15; 83 Suppl 5():109-16. PubMed ID: 7846939
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study.
    Kosior DA, Kochanowski J, Scisło P, Piatkowski R, Postuła M, Rabczenko D, Opolski G.
    Cardiol J; 2009 Oct 15; 16(6):521-7. PubMed ID: 19950088
    [Abstract] [Full Text] [Related]

  • 8. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial.
    Auer J, Weber T, Berent R, Puschmann R, Hartl P, Ng CK, Schwarz C, Lehner E, Strasser U, Lassnig E, Lamm G, Eber B, Study of Prevention of Postoperative Atrial Fibrillation.
    Am Heart J; 2004 Apr 15; 147(4):636-43. PubMed ID: 15077078
    [Abstract] [Full Text] [Related]

  • 9. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group.
    Circulation; 1995 Nov 01; 92(9):2550-7. PubMed ID: 7586356
    [Abstract] [Full Text] [Related]

  • 10. [Combination treatment of atrial arrhythmias with quinidine-verapamil].
    Gülker H, Bramann HU, Brisse B, Kuhs H.
    Med Klin; 1980 Feb 29; 75(5):196-8. PubMed ID: 6156393
    [Abstract] [Full Text] [Related]

  • 11. [Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study].
    Bellandi F, Dabizzi RP, Niccoli L, Cantini F, Palchetti R.
    G Ital Cardiol; 1996 Apr 29; 26(4):379-90. PubMed ID: 8707022
    [Abstract] [Full Text] [Related]

  • 12. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation.
    Yin Y, Dalal D, Liu Z, Wu J, Liu D, Lan X, Dai Y, Su L, Ling Z, She Q, Luo K, Woo K, Dong J.
    Eur Heart J; 2006 Aug 29; 27(15):1841-6. PubMed ID: 16825288
    [Abstract] [Full Text] [Related]

  • 13. [The effect of sotalol hydrochloride therapy on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation].
    Telichowski A, Banasiak W, Wiech K, Zeborowski J, Pieróg M, Ponikowski P, Kałka D, Lacheta W, Fuglewicz A, Telichowski C.
    Pol Merkur Lekarski; 1996 Nov 29; 1(5):303-9. PubMed ID: 9273201
    [Abstract] [Full Text] [Related]

  • 14. Atrial fibrillation: rate control often better than rhythm control.
    Prescrire Int; 2004 Apr 29; 13(70):64-9. PubMed ID: 15148984
    [Abstract] [Full Text] [Related]

  • 15. [Amiodarone and verapamil/quinidine in treatment of patients with chronic atrial fibrillation].
    Zehender M, Meinertz T, Just H.
    Z Kardiol; 1994 Apr 29; 83 Suppl 5():101-8. PubMed ID: 7846938
    [Abstract] [Full Text] [Related]

  • 16. [Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT Study. Executive committee of the investigators representing trial physicians].
    Patten M, Koch HP, Sonntag F, Lüderitz B, Meinertz T.
    Z Kardiol; 1999 Mar 29; 88(3):185-94. PubMed ID: 10355069
    [Abstract] [Full Text] [Related]

  • 17. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study.
    Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S, Paglino G, Mazzone P, Sora N, Greiss I, Santagostino A, LiVolsi L, Pappone N, Radinovic A, Manguso F, Santinelli V.
    J Am Coll Cardiol; 2006 Dec 05; 48(11):2340-7. PubMed ID: 17161267
    [Abstract] [Full Text] [Related]

  • 18. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial.
    Gulizia M, Mangiameli S, Orazi S, Chiarandà G, Piccione G, Di Giovanni N, Colletti A, Pensabene O, Lisi F, Vasquez L, Grammatico A, Boriani G, PITAGORA Study Investigators.
    Am Heart J; 2008 Jan 05; 155(1):100-7, 107.e1. PubMed ID: 18082498
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.
    Goette A, Schön N, Kirchhof P, Breithardt G, Fetsch T, Häusler KG, Klein HU, Steinbeck G, Wegscheider K, Meinertz T.
    Circ Arrhythm Electrophysiol; 2012 Feb 05; 5(1):43-51. PubMed ID: 22157519
    [Abstract] [Full Text] [Related]

  • 20. [Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study].
    Fetsch T, Burschel G, Breithardt G, Engberding R, Koch HP, Lukl J, Trappe HJ, Treese N.
    Z Kardiol; 1999 Mar 05; 88(3):195-207. PubMed ID: 10355070
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.